Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1986 1
1987 1
1988 4
1989 5
1990 4
1991 13
1992 4
1993 17
1994 14
1995 9
1996 7
1997 5
1998 9
1999 7
2000 17
2001 15
2002 8
2003 9
2004 8
2005 13
2006 10
2007 14
2008 14
2009 20
2010 9
2011 14
2012 12
2013 12
2014 7
2015 11
2016 14
2017 13
2018 14
2019 18
2020 17
2021 19
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

371 results
Results by year
Filters applied: . Clear all
Page 1
siRNA vs. shRNA: similarities and differences.
Rao DD, Vorhies JS, Senzer N, Nemunaitis J. Rao DD, et al. Among authors: nemunaitis j. Adv Drug Deliv Rev. 2009 Jul 25;61(9):746-59. doi: 10.1016/j.addr.2009.04.004. Epub 2009 Apr 20. Adv Drug Deliv Rev. 2009. PMID: 19389436 Review.
Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. Gogineni V, et al. Among authors: nemunaitis j. J Cancer. 2021 Jan 1;12(1):38-53. doi: 10.7150/jca.49406. eCollection 2021. J Cancer. 2021. PMID: 33391401 Free PMC article. Review.
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL. Rocconi RP, et al. Among authors: nemunaitis j. Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7. Lancet Oncol. 2020. PMID: 33271095 Clinical Trial.
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R, Blumenschein GR Jr, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, Seward SM, Thomas A, Kim SK, Rajagopalan P, Walter AO, Laurent D, Childs BH, Sarapa N, Elbi C, Bendell JC. Hassan R, et al. Among authors: nemunaitis jj. J Clin Oncol. 2020 Jun 1;38(16):1824-1835. doi: 10.1200/JCO.19.02085. Epub 2020 Mar 26. J Clin Oncol. 2020. PMID: 32213105 Free PMC article. Clinical Trial.
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. Hong D, et al. Among authors: nemunaitis j. Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272. Sci Transl Med. 2015. PMID: 26582900 Free PMC article. Clinical Trial.
Oncolytic viruses.
Nemunaitis J. Nemunaitis J. Invest New Drugs. 1999;17(4):375-86. doi: 10.1023/a:1006334404767. Invest New Drugs. 1999. PMID: 10759404 Review.
Oncolytic viral therapies.
Lin E, Nemunaitis J. Lin E, et al. Among authors: nemunaitis j. Cancer Gene Ther. 2004 Oct;11(10):643-64. doi: 10.1038/sj.cgt.7700733. Cancer Gene Ther. 2004. PMID: 15286681 Review.
371 results